What you need to know
- Some popular diabetes and weight loss drugs can be associated with low risk of mental, cognitive and addiction conditions.
- The authors and independent experts of the study care for certain claims, or to based on new remedies on observation studies, but the conclusions are considered statistically relevant.
A major analysis of more than 1.2 million medical records found that popular diabetes and weight loss drugs, including ozmpic and vegovi, can also reduce the risk of other health problems.
The Veterans Affairs St. Louis Health Care System, US researchers stated that drugs can be linked to “minor” risk decrease in alcohol, cannabis, opioid and other stimulating use disorders.
He also found that drugs reduced the risk of suicidal thoughts and efforts or deliberate damage by 10%; There was 18% in schizophrenia and other mental disorders, and in dementia and Alzheimer’s disease increased by 8% and 12% respectively.
This research is applied to a class of drugs called glucagon-lacquer peptide 1 receptor agonist (GLP1-RA). Ozmpic and vegovi are the most famous drugs related to this category, with active ingredients semaglutide.
Other GLP1-R include dulaglutide and liraglutide compounds.
They contain active ingredients such as semaglutide and dulaglutide and are considered to be progressing in excess weight and obesity.
Ziyad al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Al-Ali said, “GLP-1 RA medicines work on receptors that are expressed in brain areas involved in impulse control, reward and addiction-potentially in preventing hunger and addiction disorders. Explain effectiveness. “
But it also has a negative side: Al-Elie’s team found that medical records associated with the use of GLP-1 RA show known side effects such as nausea, vomiting and diarrhea. In rare cases, the functioning of the pancreas and kidney also deteriorated.
How do medicines like ozmpic and vegovi work?
While in 2023, celebrities talked about ozmpic as weight loss nectar when the drug made its way into the mainstream, it remains a drug designed to treat chronic conditions especially.
This means, whether diabetes or weight management, it is not a simple “once done” treatment, it requires a lifetime use to maintain the desired health results.
It is also determined with the rule of diet and exercise for weight loss.
Daily or weekly, GLP-1 RA repeats the body’s effect by connecting with specific receptors in the brain and triggering insulin secretions in the pancreas.
As a result, the level of glucose in the blood decreases, which is the desired result in the treatment of diabetes. It also slows down the empties of the intestines – it really delays you to go to the toilet – thus the appetite decreases.
Are diabetic medicines magical health pills?
While nutritious diet and regular exercise are accepted as other positive health results and methods to meet basic physical requirements, people with specific health requirements may require effective medicinal weight loss therapy.
Their new study shows that taking these drugs has many benefits, but it does not directly say that the use of the drug has positive health benefits – it only reflects the drugs. Probably potentially Contribute to positive results.
“This is an observation study, not a random test, and the author warns against the recommendations based on these data without any confirmation,” said David Henry, former clinical pharmacologist and evidence-based exercise researcher at Bond University, Australia. Are.” The study was not involved in the study.
“Such austerity is appropriate. Another diabetes drug, the flawed observation studies of the metformin, wrongly concluded that the drug prevents cancer. Analysis of data from random tests rejected that principle.”
And because the analysis was done on the medical records of giants, this is inconsistently applied to white men, a range accepted by researchers.
Of the 1.2 million records used for the study, 4 out of 5 were white people, about 95% were men and 80% were over 60 years of age.
Edit: Zulfikar Abbani
Main source
GLP-1 receptor agonist’s effectiveness and map of risks. Published by Yan Zee, Yayong Choi and Ziad Al-Ali in Nature Medicine. https://doi.org/10.1038/S41591-024-03412- W
